Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9905784 | European Journal of Cancer | 2005 | 5 Pages |
Abstract
Chemotherapy-induced peripheral neuropathy (CIPN) is a common phenomenon, often resulting in serious limitations in daily functioning and comprosised quality of life. Currently available toxicity grading systems typically use a combination of clinical and paraclinical parameters and relies on the judgment of clinicians and/or nurses. However, because many of the symptoms of CIPN are subjective in nature, it is only logical that an assessment of CIPN be based, at least in part, on patient self-report data. We report on the development of a patient self-report questionnaire, the CIPN20, intended to supplement the core quality of life questionnaire of the European Organization for Research and Treatment of Cancer (EORTC). Following EORTC guidelines, relevant CIPN-related issues were identified from a literature survey and interviews with health professionals (n = 15) and patients (n = 112). The resulting 20-item questionnaire was pre-tested in three languages and four countries and is currently being examined in a large, international clinical trial. The EORTC CIPN20 should provide valuable information on CIPN-related symptoms and functional limitations of patients exposed to potentially neurotoxic chemotherapeutic and/or neuroprotective agents.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
T.J. Postma, N.K. Aaronson, J.J. Heimans, M.J. Muller, J.G. Hildebrand, J.Y. Delattre, K. Hoang-Xuan, M. Lantéri-Minet, R. Grant, R. Huddart, C. Moynihan, J. Maher, R. Lucey,